aTyr Pharma, Inc. - Common Stock (ATYR)

NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of aTyr Pharma, Inc. (NASDAQ:ATYR), Marex Group PLC (NASDAQ:MRX), Cepton, Inc. (NASDAQ:CPTN), and MoonLake Immunotherapeutics (NASDAQ:MLTX). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Law Offices of Howard G. Smith reminds investors of the upcoming December 8, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased aTyr Pharma Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR) common stock between January 16, 2025 and September 12, 2025, inclusive (the “Class Period”).

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

NEW YORK - October 22, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in aTyr Pharma, Inc. (NASDAQ: ATYR) of a class action securities lawsuit.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

NEW YORK - October 21, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in aTyr Pharma, Inc. (NASDAQ: ATYR) of a class action securities lawsuit.

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired aTyr Pharma Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR) common stock between January 16, 2025 and September 12, 2025, inclusive (the “Class Period”). aTyr investors have until December 8, 2025 to file a lead plaintiff motion.

NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against aTyr Pharma, Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

NEW YORK - October 20, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in aTyr Pharma, Inc. (NASDAQ: ATYR) of a class action securities lawsuit.

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased aTyr Pharma Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR) common stock between January 16, 2025 and September 12, 2025, inclusive (the “Class Period”). aTyr investors have until December 8, 2025 to file a lead plaintiff motion.

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased aTyr Pharma Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR) common stock between January 16, 2025 and September 12, 2025, inclusive (the “Class Period”). aTyr investors have until December 8, 2025 to file a lead plaintiff motion.

NEW YORK, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against aTyr Pharma, Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

NEW YORK - October 17, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in aTyr Pharma, Inc. (NASDAQ: ATYR) of a class action securities lawsuit.

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of aTyr Pharma Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR) investors concerning the Company’s possible violations of the federal securities laws.

Law Offices of Howard G. Smith announces an investigation on behalf of aTyr Pharma Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR) investors concerning the Company’s possible violations of federal securities laws.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ATyr To Contact Him Directly To Discuss Their Options

The Law Offices of Frank R. Cruz announces an investigation of aTyr Pharma Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR) on behalf of investors concerning the Company’s possible violations of federal securities laws.

A federal class-action lawsuit has been filed against aTyr Pharma, Inc. (NASDAQ: ATYR) following a devastating 83% drop in the biotech company’s stock price after its lead drug candidate failed to meet its primary endpoint in a critical Phase 3 trial.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In aTyr (ATYR) To Contact Him Directly To Discuss Their Options

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against aTyr Pharma, Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR) and reminds investors of the December 9, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

NEW YORK, Oct. 12, 2025 (GLOBE NEWSWIRE) --

SAN DIEGO, Oct. 10, 2025 (GLOBE NEWSWIRE) --

The DJS Law Group reminds investors of a class action lawsuit against aTyr Pharma, Inc. (“aTyr” or “the Company”) (NASDAQ: ATYR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.